Three Year Follow Up Data Show a Bispecific Antibody Doubling Median Survival for Transplant Ineligible Lymphoma Patients
Three-year STARGLO data show that glofitamab plus chemotherapy roughly doubled median survival in relapsed lymphoma patients ineligible for transplant.
Medical Daily ·